PNC 27
PNC-27 is a synthetic chimeric peptide designed to selectively induce death in cancer cells. It is composed of a p53-derived HDM2-binding domain fused with a cell-penetrating peptide sequence, enabling it to target membrane-bound HDM2 proteins in cancer cells. Its mechanism is distinct from conventional chemotherapy, inducing cancer-cell death through pore formation, a process described as 'poptosis' (pore-induced necrosis).
PNC-27 Powder Manufacturer | Bulk Supply | High Purity
PNC-27 is a synthetic chimeric peptide designed to selectively induce death in cancer cells. It is composed of a p53-derived HDM2-binding domain fused with a cell-penetrating peptide sequence, enabling it to target membrane-bound HDM2 proteins in cancer cells. Its mechanism is distinct from conventional chemotherapy, inducing cancer-cell death through pore formation, a process described as 'poptosis' (pore-induced necrosis).
| Item | Details |
|---|---|
| Name | PNC-27 |
| Chemical Class | Synthetic peptide |
| CAS Number | |
| Molecular Formula | Not publicly disclosed |
| Molecular Weight | ~2,000–3,000 Da (approx., depending on sequence form) |
| Sequence | p53-derived peptide linked to membrane-penetrating peptide (MDM2-binding domain) |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥98% (HPLC tested) |
| Solubility | Soluble in sterile water or PBS |
| Storage | -20°C, dry and dark conditions |
| Form | Lyophilized peptide powder |
| Stability | Stable under recommended storage; avoid repeated freeze-thaw cycles |
| Application | Research use only |
Research & Cancer Applications
• Active against diverse cancer cell lines: leukemia, breast, colon, pancreatic, melanoma, ovarian.
• Selectivity: Spares normal fibroblasts and endothelial cells without membrane HDM2.
• Imaging: Electron microscopy confirms transmembrane pore formation in tumor cells.
• Ex Vivo: Demonstrated cytotoxicity in primary ovarian cancer samples.
• Animal Models: Tumor regression reported in xenografts with minimal systemic toxicity.
• Mechanistic Advantage: Works independently of p53 mutation status.
Safety & Regulatory Notes
- FDA Warning: Explicit caution against PNC-27 as a cancer treatment (2017).
- Adverse Events: Severe GI hemorrhage documented in case report.
- Risks: Human dosing, toxicology, long-term effects unknown.
- Product Concerns: Online sources may have inconsistent peptide purity.
PNC-27 vs FOXO4-DRI vs Nutlin-3
|
Feature |
PNC-27 |
FOXO4-DRI |
Nutlin-3 |
|
Mechanism |
Binds HDM2 in membranes, forms pores → necrosis |
Blocks FOXO4-p53 → apoptosis of senescent cells |
Blocks MDM2-p53 → reactivates p53 |
|
Target Cells |
Cancer cells with membrane HDM2 |
Senescent cells (anti-aging/fibrosis research) |
MDM2-amplified cancers with wild-type p53 |
|
Evidence |
Cell, ex vivo, animal studies |
Cell & mouse studies only |
Clinical candidates in trials |
|
Limitations |
FDA warning; case reports of harm |
Experimental; human safety unknown |
Toxicities; dependent on tumor p53 status |
certifications
Shipping methods
| Country | Delivery time |
| Untied states | 7-15 DAYS |
| Australia | 7-12 DAYS |
| Germany | 7-12 DAYS |
| Canada | 8-10 DAYS |
| New zealand | 7-10 DAYS |
| Uk | 5-10 DAYS |
| Thailand | 5-8 DAYS |
| Malaysia | 5-8 DAYS |
| Vietnam | 5-8 DAYS |
The delivery time shown above is an estimate. Shipping routes and freight capacity may change from time to time. For the most accurate delivery schedule, please contact us directly.
Payment terms
Hot Tags: pnc 27, China pnc 27 manufacturers, suppliers, factory, pnc 27 cancer, pnc 27 anti cancer peptide, foxo4 dri 10mg, anticancer peptides, foxo4 dri 5mg, anti cancer peptides
Send Inquiry
